Mr. Hugh MacNaught reports

VENTRIPOINT ISSUES SHARES FOR PAYMENT OF DEBENTURE INTEREST

Ventripoint Diagnostics Ltd. has received approval from the TSX Venture Exchange and issued 555,699 common shares for the payment of an aggregate of $61,217 of interest owing on certain outstanding convertible debentures issued by the corporation on Sept. 20, 2024, March 21, 2025, Sept. 2, 2025, and Oct. 14, 2025. The convertible debentures bear interest at the rate of 10 per cent per annum, payable every six months. The shares will be issued at a deemed price of 11 cents and are subject to a hold period of four months and one day. The issuance of the shares will not create a control person of the corporation.

The offering is a related-party transaction within the meaning of TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions) as certain insiders of the corporation received an aggregate of 15,778 shares. The corporation is relying on exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and (b) and 5.7(a) and (b) of MI 61-101 as the corporation is not listed on a specified market, the fair market value of the participation in the transactions by insiders does not exceed 25 per cent of the market capitalization of the corporation as determined in accordance with MI 61-101 and the fair market value of the transactions is not more than $2.5-million.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.